Future proofing the UK’s research ecosystem in the face of global changeThe UK is a powerhouse of clinical research but maintaining that leading position – and all the benefits Share XFuture proofing the UK’s research ecosystem in the face of global changehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-proofing-the-uks-research-ecosystem-in-the-face-of-global-change/
ABPI looks internally for new CEO, naming Richard TorbettThe new chief executive of the Association of the British Pharmaceutical Industry (ABPI) will be Dr Richard Torbett Share XABPI looks internally for new CEO, naming Richard Torbetthttps://pharmaphorum.com/news/abpi-looks-internally-for-new-ceo-naming-richard-torbett/
ABPI’s blueprint to build a pharma powerhouse in uncertain political timesThe UK is in the grips of election fever, but whoever takes the reins on 13 December will Share XABPI’s blueprint to build a pharma powerhouse in uncertain political timeshttps://pharmaphorum.com/r-d/views-analysis-r-d/abpis-blueprint-to-build-a-pharma-powerhouse-in-uncertain-pollical-times/
UK startup Ervaxx targets ‘dark matter’ of human genomeAfter two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing Share XUK startup Ervaxx targets ‘dark matter’ of human genomehttps://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/
Blow to Novartis as NICE rejects migraine drug Aimovig againAfter NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with Share XBlow to Novartis as NICE rejects migraine drug Aimovig againhttps://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/
Science sector lauds UK’s visa scheme, but repeats no-deal Brexit warningBoris Johnson has ordered a new fast-track visa scheme to make it easier for top scientists to work Share XScience sector lauds UK’s visa scheme, but repeats no-deal Brexit warninghttps://pharmaphorum.com/news/science-sector-lauds-uks-visa-scheme-but-repeats-no-deal-brexit-warning/
Boris Johnson announces £1.8bn cash boost for NHSNew UK prime minister Boris Johnson has pledged a £1.8 billion cash injection for the NHS as he Share XBoris Johnson announces £1.8bn cash boost for NHShttps://pharmaphorum.com/news/boris-johnson-announces-1-8bn-cash-boost-for-nhs/
VPAS 2024: What should industry consider next time?The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded Share XVPAS 2024: What should industry consider next time?https://pharmaphorum.com/views-analysis-market-access/vpas-2024-what-should-industry-consider-next-time/
Market access round-up: the UK opens up to innovationWhen it comes to market access in the UK, the public’s eye has mostly been on the ongoing Share XMarket access round-up: the UK opens up to innovationhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-the-uk-opens-up-to-innovation/
